title: miR-21 expression predicts prognosis in diffuse large B-cell lymphoma.
abstract: BACKGROUND
  Expression patterns of microRNAs in serum are involved in potentially biomarkers for various diseases. The aim of the study was to investigate the expression level of miR-21 in diffuse large B cell lymphoma (DLBCL) and its prognostic value.
  
  
  METHODS
  Real-time quantitative polymerase chain reaction (qRT-PCR) was used to measure miR-21 levels in serum samples from 112 patients with DLBCL as well as in serum samples from 45 healthy controls. The associations between miR-21 expression and clinicopathologic parameters and overall survival of the patients, were analyzed by chi-square test and Kaplan-Meier method. The Cox proportional hazards regression analyses were performed to estimate the prognostic values for patient survival prediction.
  
  
  RESULTS
  We found that serum miR-21 expression was markedly upregulated in patients with DLBCL than healthy controls. Increased miR-21 expression was significantly correlated with B symptoms, IPI score, CHOP-like treatment and Rituximab (all Ps<0.05). Moreover, DLBCL patients with miR-21 higher expression have shown significantly worse overall survival than those with lower miR-21 expression. And miR-21 expression was an independent prognostic marker of overall survival in a multivariate analysis (P=0.001, HR: 4.404, 95% CI: 1.770-10.956).
  
  
  CONCLUSIONS
  The results of the present study suggested miR-21 expression level could be a novel potential biomarker for DLBCL prognosis.
authors.affiliation: Department of Hematology, Tianjin Medical University General HospitalTianjin 300052, China; Department of Hematology, Shangyu People's HospitalShangyu 312300, Shaoxing, Zhejiang, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Hematology, Tianjin Medical University General Hospital Tianjin 300052, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Fu
authors.affiliation: Department of Hematology, Yuebei People's Hospital Shaoguan 512000, Guangdong, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Yang
authors.affiliation: Department of Hematology, Shangyu People's Hospital Shangyu 312300, Shaoxing, Zhejiang, China.
authors.forename: Weiping
authors.initials: W
authors.lastname: Tu
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood* / Q000235:genetics*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D016016:Proportional Hazards Models; D060888:Real-Time Polymerase Chain Reaction; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014408:Biomarkers, Tumor; C524940:MIRN21 microRNA, human; D035683:MicroRNAs; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: MicroRNA-21; diffuse large B-cell lymphoma; prognosis
references.citation: Neurol Sci. 2014 Feb;35(2):233-8
references.pmid: 23832112
references.citation: Eur J Haematol. 2014;92(5):407-12
references.pmid: 24400911
references.citation: Clin Res Hepatol Gastroenterol. 2014 Dec;38(6):715-9
references.pmid: 25150373
references.citation: Oncotarget. 2015 Jun 20;6(17):15035-49
references.pmid: 25909227
references.citation: N Engl J Med. 2002 Jun 20;346(25):1937-47
references.pmid: 12075054
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Nat Rev Genet. 2004 Jul;5(7):522-31
references.pmid: 15211354
references.citation: Blood. 1994 Sep 1;84(5):1361-92
references.pmid: 8068936
references.citation: Nat Rev Cancer. 2005 Apr;5(4):251-62
references.pmid: 15803153
references.citation: Mod Pathol. 2005 Aug;18(8):1113-20
references.pmid: 15920553
references.citation: N Engl J Med. 2005 Oct 27;353(17):1793-801
references.pmid: 16251535
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61
references.pmid: 16461460
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: BioDrugs. 2007;21(2):97-104
references.pmid: 17402793
references.citation: J Biol Chem. 2007 May 11;282(19):14328-36
references.pmid: 17363372
references.citation: Int J Cancer. 2007 Sep 1;121(5):1156-61
references.pmid: 17487835
references.citation: Arch Pathol Lab Med. 2008 Jan;132(1):118-24
references.pmid: 18181663
references.citation: Cancer J. 2008 Jan-Feb;14(1):1-6
references.pmid: 18303474
references.citation: Br J Haematol. 2008 May;141(5):672-5
references.pmid: 18318758
references.citation: Oncogene. 2008 Jul 17;27(31):4373-9
references.pmid: 18372920
references.citation: Br J Haematol. 2008 Sep;142(5):732-44
references.pmid: 18537969
references.citation: Int J Mol Med. 2010 Dec;26(6):819-27
references.pmid: 21042775
references.citation: Br J Cancer. 2010 Nov 9;103(10):1617-26
references.pmid: 20978511
references.citation: J Physiol Biochem. 2011 Mar;67(1):129-39
references.pmid: 20981514
references.citation: Blood. 2011 Mar 17;117(11):3140-6
references.pmid: 21200023
references.citation: Oncology. 2010;79(3-4):313-20
references.pmid: 21412018
references.citation: Cell Death Dis. 2011;2:e151
references.pmid: 21525938
references.citation: J Biol Chem. 2011 May 27;286(21):19127-37
references.pmid: 21471222
references.citation: Oncogene. 2011 May 26;30(21):2433-42
references.pmid: 21278789
references.citation: Ann Hematol. 2012 Apr;91(4):553-9
references.pmid: 21987025